Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Administration
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Administration

2 evidence topics · 2 sources

Nasogastric administration and serum concentrations

“Tirabrutinib concentrations may increase with nasogastric administration using the simple suspension method.” (opens the source at this quote in a new tab)
“In patients unable to ingest tablets orally, careful clinical monitoring is warranted, and therapeutic drug monitoring may be considered in select cases.” (opens the source at this quote in a new tab)

Nasogastric administration in an elderly patient

“We report that tirabrutinib was administered via nasogastric tubes to treat an elderly patient with primary central nervous system lymphoma (PCNSL).” (opens the source at this quote in a new tab)